Healthcare entity
Bundibugyo ebolavirus is most often covered alongside World Health Organization, which appears in 4 of these 7 stories. regulation accounts for 5 of the 7 tracked stories, while 2 other categories carry the remainder. Each story carries 2.3 original sources on average, compared with 3.9 for the broader beat in this window.
Last mentioned: Jul 13, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Bundibugyo ebolavirus is most often covered alongside World Health Organization, which appears in 4 of these 7 stories. regulation accounts for 5 of the 7 tracked stories, while 2 other categories carry the remainder. Each story carries 2.3 original sources on average, compared with 3.9 for the broader beat in this window. The 28-day window averages about 1.8 stories each week. The busiest single day carried 2. Sentiment skews more negative than the wider beat, at 43% negative against 31% across all 261 Healthcare stories in the same window. Their average consequence score of 6.9 runs above the beat's 6.2 for that window. This profile follows 7 Healthcare stories mentioning Bundibugyo ebolavirus across the period from July 11, 2026 to August 7, 2026.
Computed from the 7 stories linked to this entity, with beat comparisons drawn from all 261 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Bundibugyo ebolavirus. Shared-story counts are live from our verified record — not editorial picks.
First-in-Human Trial Begins
A Phase 1 clinical trial of the ChAdOx1-biEBOV vaccine, enrolling 50 healthy adults, commences with 4,000 doses supplied by the Serum Institute of India.
WHO sounds alarm
WHO reports that 80% of new cases are from unknown chains of transmission; striking workers agree to return if paid within 72 hours.
Ethics Approval Received
NanoViricides announces National Ethics Committee approval for Phase II trial of NV-387 oral gummies for Ebola.
Health worker strike
Dozens of healthcare workers at an Ebola treatment centre in Bunia go on strike over unpaid salaries and bonuses.
Outbreak Worsens
DRC public health institute reports 1,926 confirmed Ebola cases and 702 deaths, with spread to Haut-Uele and Tshopo provinces.
Africa CDC declares fastest-growing outbreak
Africa CDC states the outbreak is the fastest-growing Ebola epidemic on the continent as news of the spread to new provinces circulates.
Health workers protest
Ebola response workers protest outside three treatment centers in Bunia over unpaid wages; police disperse one demonstration at CME.
Government report released
A government report published late Wednesday confirms 1,759 total cases and 600 deaths, with two new suspected cases in Kisangani, Tshopo province—one with no known epidemiological link.
WHO reveals outbreak toll
WHO Director-General announces 1,400+ cases and 438 deaths, confirming the trial's start and expressing hope for effective therapies.
Clinical trials scheduled
Health workers prepare for Ebola clinical trials at the Evangelical Medical Center in Bunia, Ituri province.
Trial launch and first enrollment
Researchers begin the first-ever Ebola treatment trial for Bundibugyo virus at Bunia's Evangelical Medical Center, enrolling the first participant to evaluate remdesivir and MBP134.
WHO Declares Public Health Emergency
The World Health Organization declares the Bundibugyo Ebola outbreak in the DRC and Uganda a Public Health Emergency of International Concern (PHEIC), accelerating vaccine development and funding.
Outbreak declared
DRC authorities declare a new Ebola outbreak caused by the Bundibugyo virus, after weeks of undetected transmission according to WHO.
Outbreak identified
Congo detects an outbreak of the rare Bundibugyo Ebola virus in the eastern part of the country.
With Ebola cases surpassing 4,000 and deaths at 1,850, African health authorities are shifting strategy toward community mobilization. The outbreak highlights critical gaps in public health infrastructure, from surveillance to testing, and the need for stronger local engagement.
Source: torontotelegraph.com · english.news.cn
With 702 deaths and a spreading Bundibugyo outbreak, the strike at Congo's main Ebola treatment center threatens to accelerate transmission. The walkout exposes systemic weaknesses in outbreak workforce support that could undermine the entire containment effort.
A WHO-backed clinical trial in conflict-hit Congo is testing remdesivir and MBP134 for the Bundibugyo strain, spotlighting the extreme operational challenges of providing care and conducting research in fragile health systems.
Source: sun-sentinel.com
Congo’s overstretched health system is shown by 80% of new Ebola cases arising outside contact lists, a worker strike, and a $300M funding gap—highlighting the need for digital surveillance and workforce stability.
A phase 1 trial of an adenovirus-vectored vaccine for the Bundibugyo Ebola strain is underway, enrolling 50 adults. With 620,000 doses pre-manufactured, the trial highlights rapid pandemic response but underscores immediate public health challenges as the outbreak’s death toll exceeds 700.
Source: deccanchronicle.com · seattletimes.com
As the DRC Ebola outbreak surpasses 1,900 cases with 702 fatalities, NanoViricides’ oral NV-387 gummies gain ethics approval for a Phase II trial. The chewable format could overcome logistical hurdles in resource-limited regions, potentially reshaping epidemic management if proven effective.
The public health crisis deepens as Ebola spreads to previously unaffected areas, with response hampered by funding gaps, worker protests, and no approved countermeasures.
Source: sconeadvocate.com.au · timesfreepress.com
Bundibugyo ebolavirus is linked from 7 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
